O
Ocugen
Biotech & Life Sciences · Aurora, United States · Founded 2013 · IPO 2014
A biotech company specializing in vaccines and gene therapies, focusing on public health and unmet medical needs, with a breakthrough modifier gene therapy platform for multiple retinal diseases and… MoreLess
Ocugen is a fully integrated, patient-centric biotech company dedicated to developing and commercializing novel gene and cell therapies and vaccines. The company focuses on addressing unmet medical needs through innovative solutions. Ocugen's core offerings include a breakthrough modifier gene therapy platform aimed at treating multiple retinal diseases with a single product, advanced vaccine research to combat COVID-19, and cell therapy targeting orthopedic diseases lacking effective treatments. The company operates in the biotechnology sector, serving patients worldwide by leveraging extensive experience from both public and private sectors. Ocugen generates revenue through the development, commercialization, and licensing of its proprietary therapies and vaccines.
Keywords: gene therapy, cell therapy, vaccines, retinal diseases, COVID-19, orthopedic diseases, biotechnology, commercialization, patient-centric, innovative solutions.
Company overview
Ocugen company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2013
- Headquarters
- Aurora, United States
- Employees
- 129
- Open positions
- 9
- Dealroom signal
- 88.5
Valuation & funding
Ocugen funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | May 2026 | $130M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Jan 2026 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Dec 2025 | $0 | — | Janus Henderson Investors | ↗ |
| POST IPO EQUITY✓Other financing | Aug 2025 | $20M | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Nov 2024 | $30M | — | Avenue Capital Group | ↗ |
| POST IPO EQUITY✓Other financing | Jul 2024 | Undisclosed | ↗ | ||
| POST IPO EQUITY✓Other financing | May 2023 | Undisclosed | ↗ | ||
| SECONDARY✓Other financing | Feb 2022 | Undisclosed | ↗ | ||
| POST IPO EQUITY✓Other financing | Feb 2021 | Undisclosed | — | ||
| SERIES B✓Equity / VC | Jun 2017 | John Zhang · Abdi Ibrahim Pharmaceuticals | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Ocugen website traffic
Latest recorded traffic for Ocugen is 13K monthly website visits, down 23.5% over the last three months. Ocugen's team grew 26.5% over the past year.
Hiring
Open positions at Ocugen
Current openings linked to this company in Dealroom.
Comparisons
Ocugen compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Ocugen's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Ocugen has talent and traffic
team presence
In the news
Latest news about Ocugen
Recent press, funding announcements, and product moves mentioning Ocugen — open to read from the original sources.
Market sentiment
What the market is saying about Ocugen
An AI-synthesized read of the highest-engagement posts about Ocugen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ocugen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.